BRCA1/2胚系突变乳腺癌患者放疗后的结局:多样本队列研究
该回顾性队列研究纳入2213例接受BRCA1/2基因检测的I-III期乳腺癌患者,比较BRCA1/2致病突变携带者与无突变者的放疗后结局。中位随访7.4年,两组10年局部区域复发率和疾病特异性死亡率无显著差异,BRCA1/2突变组急性≥3级放疗相关毒性为5.4%,晚期≥3级为0.4%。结论支持对BRCA1/2胚系突变患者按标准指征进行放疗。
要点
- BRCA1/2突变与无突变者10年局部区域复发率和疾病特异性死亡率无显著差异。
- BRCA1/2突变组急性≥3级放疗相关毒性5.4%,晚期≥3级0.4%。
- BRCA1/2突变组未观察到野内非乳腺第二原发癌。
核心结论
- 在BRCA1/2胚系致病突变乳腺癌患者中,放疗后的肿瘤学结局与无突变者相似,支持按标准指征使用放疗。
研究设计与样本
- 回顾性队列研究,纳入2213例在MD Anderson接受根治性手术和放疗并完成BRCA1/2基因检测的临床I-III期乳腺癌女性。
- 124例携带BRCA1突变,100例携带BRCA2突变,1394例(63%)接受区域淋巴结放疗。
- 中位随访7.4年(95%CI 7.1-7.7年),比较BRCA1/2致病突变状态与局部区域复发、疾病特异性死亡、毒性和第二原发癌的关系。
主要发现
- BRCA1/2突变组未观察到野内非乳腺第二原发癌。
- BRCA1/2突变组急性和晚期≥3级放疗相关毒性发生率分别为5.4%(n=12)和0.4%(n=1)。
临床怎么用
- 对于携带BRCA1/2胚系致病突变的乳腺癌患者,可按标准指征进行放疗,无需因突变状态而省略或调整放疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: BRCA1/2 pathogenic variant (PV) mutations confer radiation sensitivity preclinically, but there are limited data regarding breast cancer outcomes after radiation therapy (RT) among patients with documented BRCA1/2 PV mutations versus no PV mutations. METHODS AND MATERIALS: This retrospective cohort study included women with clinical stage I-III breast cancer who received definitive surgery and RT and underwent BRCA1/2 genetic evaluation at the The University of Texas MD Anderson Cancer Center. Rates of locoregional recurrence (LRR), disease-specific death (DSD), toxicities, and second cancers were compared by BRCA1/2 PV status. RESULTS: Of the 2213 women who underwent BRCA1/2 testing, 63% self-reported their race as White, 13.6% as Black/African American, 17.6% as Hispanic, and 5.8% as Asian/American Indian/Alaska Native; 124 had BRCA1 and 100 had BRCA2 mutations; and 1394 (63%) received regional nodal RT. The median follow-up time for all patients was 7.4 years (95% confidence interval [CI], 7.1-7.7 years). No differences were found between the groups with and without BRCA1/2 PV mutations in 10-year cumulative incidences of LRR (with mutations: 11.6% [95% CI, 7.0%-17.6%]; without mutations: 6.6% [95% CI, 5.3%-8.0%]; P = .466) and DSD (with mutations: 12.3% [95% CI, 8.0%-17.7%]; without mutations: 13.8% [95% CI, 12.0%-15.8%]; P = .716). On multivariable analysis, BRCA1/2 status was not associated with LRR or DSD, but Black/African American patients (P = .036) and Asians/American Indians/Alaska Native patients (P = .002) were at higher risk of LRR compared with White patients, and Black/African American patients were at higher risk of DSD versus White patients (P = .004). No in-field, nonbreast second cancers were observed in the BRCA1/2 PV group. Rates of acute and late grade ≥3 radiation-related toxicity in the BCRA1/2 PV group were 5.4% (n = 12) and 0.4% (n = 1), respectively. CONCLUSIONS: Oncologic outcomes in a diverse cohort of patients with breast cancer who had a germline BRCA1/2 PV mutation and were treated with RT were similar to those of patients with no mutation, supporting the use of RT according to standard indications in patients with a germline BRCA1/2 PV mutation.
引用
- Chapman BV, Liu D, Shen Y, et al. Outcomes After Breast Radiation Therapy in a Diverse Patient Cohort With a Germline BRCA1/2 Mutation. Int J Radiat Oncol Biol Phys. 2021. PMID: 34610390. doi:10.1016/j.ijrobp.2021.09.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。